Barclays Maintains Overweight on HealthEquity, Raises Price Target to $115
Barclays analyst Peter Warendorf maintains HealthEquity (NASDAQ:HQY) with a Overweight and raises the price target from $110 to $115.
Stocks · News reference
8-K filing — HEALTHEQUITY, INC. (HQY)
Filed: 2026-09-30 AccNo: 0001428336-26-000045 Size: 168 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Deutsche Bank Maintains Buy on HealthEquity, Raises Price Target to $142
Why HealthEquity Stock Sank This Week
HealthEquity stock fell 8.6% this week despite delivering sales and earnings beats in its fiscal Q2 report. The company posted adjusted EPS of $1.24 on revenue of $350.7 million, both exceeding analyst expectations. However, management's marginal increase to full-year revenue guidance and unchanged adjusted EPS guidance disappointed investors who were expecting stronger forward guidance.